Novartis Slips As Generics Bite Into Its Heart-Failure Drug Sales In Mixed Third Quarter

ANALYSIS: Are Prediction Markets Turning Brokers Into Bookies? Notably, sales of heart-failure treatment Entresto fell 1%, in constant currency, to $1.88 billion. Entresto is facing off with generic competition. Generics took a 7 percentage-point hit on Entresto sales, Novartis said in its news release. Novartis reaffirmed its outlook for the year. Sales are expected to grow by a high single-digit percentage, while core operating income is projected to increase by a low-teens percentage. Analysts projected ...